Testicular self‐examination and testicular cancer: a cost‐utility analysis

Abstract The United States Preventive Services Task Force ( USPSTF ) has recommended against testicular self‐examinations ( TSE ) or clinical examination for testicular cancer screening. However, in this recommendation there was no consideration of the significant fiscal cost of treating advanced disease versus evaluation of benign disease. In this study, a cost‐utility validation for TSE was performed. The cost of treatment for an advanced‐stage testicular tumor (both seminomatous and nonseminomatous) was compared to the cost of six other scenarios involving the clinical assessment of a testicular mass felt during self‐examination (four benign and two early‐stage malignant). Medicare reimbursements were used as an estimate for a national cost standard. The total treatment cost for an advanced‐stage seminoma ($48,877) or nonseminoma ($51,592) equaled the cost of 313–330 benign office visits ($156); 180–190 office visits with scrotal ultrasound ($272); 79–83 office visits with serial scrotal ultrasounds and labs ($621); 6–7 office visits resulting in radical inguinal orchiectomy for benign pathology ($7,686) or 2–3 office visits resulting in treatment and surveillance of an early‐stage testicular cancer ($17,283: seminoma, $26,190: nonseminoma). A large number of clinical evaluations based on the TSE for benign disease can be made compared to the cost of one missed advanced‐stage tumor. An average of 2.4 to 1 cost benefit ratio was demonstrated for early detected testicular cancer versus advanced‐stage disease.